Y-Intercept (HK)’s Larimar Therapeutics LRMR Stock Holding History

Y-Intercept (HK)’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,369	Closed	-$51.5K	–	1536
2023 Q1	$51.5K	Buy	+11,369	New	+$59.4K	0.01%	1100

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Y-Intercept (HK)'s LRMR Position: Q2 2023 in Review

Y-Intercept (HK) sold out of Larimar Therapeutics (LRMR) in Q2 2023, closing a stake of 11,369 shares — an estimated $51.5K sold.

Y-Intercept (HK) first reported a position in LRMR in Q1 2023 and held it in 1 quarter. The position peaked at $51.5K in Q1 2023. 65 funds tracked by Wall St. Rank hold LRMR as of Q2 2023.

Y-Intercept (HK) reported no remaining Larimar Therapeutics position as of Q2 2023 after selling out during the quarter.
Y-Intercept (HK) sold 11,369 Larimar Therapeutics shares in Q2 2023, an estimated $51.5K.
Y-Intercept (HK) first reported a position in Larimar Therapeutics in Q1 2023 and held it in 1 quarter.
Y-Intercept (HK)'s Larimar Therapeutics position peaked at $51.5K in Q1 2023.
65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2023.

Based on Y-Intercept (HK)'s 13F filing for Q2 2023, filed 14 Aug 2023.